Dr. Babak Edraki, MD
Claim this profileJohn Muir Medical Center-Concord Campus
Studies Breast Cancer
Studies Ovarian Cancer
8 reported clinical trials
25 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage II
Stage I
2Ovarian Cancer
Stage IV
Stage III
BRCA1 positive
Affiliated Hospitals
Clinical Trials Babak Edraki, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
More about Babak Edraki, MD
Clinical Trial Related2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Babak Edraki, MD has experience with
- Carboplatin
- Paclitaxel
- External Beam Radiation Therapy
- Bevacizumab
- Oregovomab
- Behavioral Dietary Intervention
Breakdown of trials Babak Edraki, MD has run
Breast Cancer
Ovarian Cancer
Fallopian Tube Cancer
Serous Cystadenocarcinoma
Esophageal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Babak Edraki, MD specialize in?
Is Babak Edraki, MD currently recruiting for clinical trials?
Are there any treatments that Babak Edraki, MD has studied deeply?
What is the best way to schedule an appointment with Babak Edraki, MD?
What is the office address of Babak Edraki, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.